Wasatch Clinical Research, LLC
Welcome,         Profile    Billing    Logout  
 4 Trials 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
George, Karen
NCT05217927 / 2021-005239-22: Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

Completed
4
698
Europe, Canada, US
Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing
Pfizer, Biohaven Pharmaceuticals Holding Company Limited, Pfizer Inc.
Migraine
10/24
12/24
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Terminated
2/3
538
US
BHV-3500 (zavegepant), Placebo
Pfizer
Migraine
03/24
03/24
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Recruiting
2
230
US
HDV-Lispro, HDV-L, Lispro, LIS
Diasome Pharmaceuticlas, Inc.
Diabetes Mellitus, Type 1
06/25
12/25
Patel, Atul
NCT04967664 / 2021-001409-64: Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Active, not recruiting
3
409
Europe, US
Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system
Averitas Pharma, Inc., Averitas Pharma, Inc.
Post Surgical Neuropathic Pain
01/25
08/25
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Terminated
2/3
538
US
BHV-3500 (zavegepant), Placebo
Pfizer
Migraine
03/24
03/24
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
Cupelo, Robert
NCT06015282: The Celljuvant Study: a Phase 3 Immunogenicity and Safety Study of AQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Active, not recruiting
3
1083
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
05/25
05/25
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
320
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
275
US, RoW
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
179
US, RoW
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
01/25
05/25
MIND, NCT02720445: Memory Improvement Through Nicotine Dosing () Study

Active, not recruiting
2
380
US
Nicotine Transdermal Patch, Placebo Patch
University of Southern California, National Institute on Aging (NIA), Vanderbilt University, Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment
09/25
09/25
BIO-HERMES-001, NCT04733989: A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

Completed
N/A
1002
US
Biomarker Data Collection
GAP Innovations, PBC
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
11/22
11/22
Hanks, Annie
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Completed
3
1319
Canada, US
MR-100A-01, Transdermal contraceptive delivery system
Mylan Technologies Inc., Mylan Inc.
Contraception
01/25
01/25
MODEL, NCT05516992: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

Active, not recruiting
3
417
US
SB-01 For Injection, Sham Needle
Spine BioPharma, Inc, MCRA
Lumbar Degenerative Disc Disease
02/25
08/25
NCT05603754: A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)

Completed
3
496
US
Lorecivivint, SM04690, Placebo, Vehicle
Biosplice Therapeutics, Inc., NBCD A/S
Knee Osteoarthritis
02/24
02/24
C4951003, NCT04743141: Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Recruiting
3
200
Europe, US
Rimegepant (PF-07899801)
Pfizer
Acute Treatment of Migraine
06/27
06/27
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting
3
2100
Europe, Canada, Japan, US, RoW
Rimegepant/BHV3000, Matching placebo
Pfizer
Pediatric Migraine
01/29
01/29
Hope, NCT05637801: A Pivotal Study of Sensory Stimulation in Alzheimer's Disease ( Study, CA-0011)

Recruiting
N/A
600
US
Sensory Stimulation System (GS120) - Active, Sensory Stimulation System (GS120) - Sham
Cognito Therapeutics, Inc.
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
11/25
12/25
Rabin, Mara Lee
NCT05264506: Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Terminated
3
2007
US
NOMAC-E2 COC, Nomegestrol acetate / estradiol
Organon and Co, IQVIA Inc., OSTAtistics
Contraception
01/24
01/24
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
Jarvi, Albert O
NCT04967664 / 2021-001409-64: Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Active, not recruiting
3
409
Europe, US
Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system
Averitas Pharma, Inc., Averitas Pharma, Inc.
Post Surgical Neuropathic Pain
01/25
08/25
MODEL, NCT05516992: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

Active, not recruiting
3
417
US
SB-01 For Injection, Sham Needle
Spine BioPharma, Inc, MCRA
Lumbar Degenerative Disc Disease
02/25
08/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
Schlisman, Alison
Polaris-AD, NCT05531526: Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease

Recruiting
3
1150
Europe, US, RoW
AR1001, Placebo
AriBio Co., Ltd.
Alzheimer Disease
12/25
12/27

Download Options